Performance for
OA knee pain relief
that matters

After 3 injections,
patients had
significantly less
pain associated with
5 basic functions
The effectiveness and safety of EUFLEXXA was shown to be comparable to another HA product in a head-to-head clinical trial. The study was conducted in 321 patients with
OA knee pain over a 12-week period.*
Pain improvement with EUFLEXXA was 62% (P<0.0001) vs 55% with the other product (P<0.0001).†
Most common adverse events include joint pain (11/160), increase in blood pressure (3/160), joint swelling (3/160), feeling of sickness (3/160), tingling (2/160), back pain (1/160), nausea (1/160), skin irritation (1/160).
HA=hyaluronic acid; OA=osteoarthritis.
*Questions based on the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). WOMAC is an internationally recognized and widely used set of standardized questionnaires that allow healthcare providers to assess the condition of patients with osteoarthritis of the knee and hip. Measures include pain, stiffness, and physical functioning of the joints.
†Improvements from baseline were statistically significant for both treatment groups. EUFLEXXA = (101/160)
In a clinical trial, significantly fewer unilateral*
patients treated with
EUFLEXXA
had a need for acetaminophen vs another
HA (P=0.001).
HA=hyaluronic acid; OA=osteoarthritis.
Acetaminophen was the only additional medication provided.
*Unilateral means OA knee pain in one knee.
†EUFLEXXA 51% (34 of 67 patients with unilateral knee pain)
another HA 18% (13 of 72 patients with unilateral knee pain).
OA=osteoarthritis.
*In the 12-week study, side effects caused by EUFLEXXA were
joint pain (11/160), increase in blood pressure
(3/160), joint
swelling (3/160), feeling of sickness (3/160), tingling (2/160),
back pain (1/160), nausea (1/160), skin irritation (1/160), and tenderness in study knee (1/160).
#1 prescribed HA is based on rolling 12-month average of IQVIA claims data from unique patients (August 2018-August 2019).
EUFLEXXA (1% sodium hyaluronate) is used to relieve knee pain due to osteoarthritis. It is used for patients who do not get enough relief from simple pain medications such as acetaminophen or from exercise and physical therapy.
EUFLEXXA is only for injection into the knee, performed by a doctor or other qualified healthcare professional.
You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.FDA.gov/medwatch or call 1-800-FDA-1088.
You may also contact Ferring Pharmaceuticals Inc. at 1-888-FERRING.